Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How much is that revenue stream worth to a potential buyer today?
Good points. Lots of tailwinds behind this stock for a long while ahead.
Good find. Thanks. Pharmas aren't just using HALO Subcu technology as a patent extender, they're putting it in place much earlier in the lifecycle of the drugs.
Looks like it's aiming to fill that gap at ~$34
Friday night news dump.
New All-time intraday high today.
Benchmark Securities raises PT to $46 from $34, keeps buy rating
JMP Securities raises PT to $45 from $34. Maintains outperform.
RPRX would definitely be a good fit. Their Market cap is 25 billion and I'd say HALO could be acquired for about half of that price co it's in the realm of possibility in so far as proportionate size.
I do think Helen would like to sell her stake and the best way to unload that is via a buyout so she's motivated, IMHO.
Would the transformation of HALO from an independent company into a subsidiary of a larger pharma company actually tend to put a damping effect on deals with a wide variety of collaborators, thus reducing the income stream? Currently HALO has no competitors and can deal with each prospective customer in a neutral manner.
I've been re-thinking the buyout hypothesis and am wondering what you all think about *why* a company might want to purchase Halozyme. What would be the strategic pros and cons of such a deal, as heard in the boardrooms of the potential buyers?
In light of these developments I'm raising my assessment of the *current* value of HALO to $45 per share from $40 and by mid-2021 from $50 to $55-60.
They buyout price, if any has just moved again also, but I don't have a good estimate of that, except to say it's now likely north of $100.
Now we know why those options went off last week.
Halozyme Raises FY20 GAAP EPS Guidance From $0.80-$0.85 To $0.90-$0.95 vs $0.86 Est., Raises Sales Guidance From $250M-$260M To $265M-$275M vs $255.12M
New Deal Announced.
-----------------------------------------------------------
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Techn...
November 23 2020 - 08:00AM
PR Newswire (US)
Alert
Print
Share On Facebook
DUBLIN and SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives Horizon exclusive access to Halozyme's ENHANZE® drug delivery technology for subcutaneous (SC) formulation of medicines targeting IGF-1R. Horizon intends to use ENHANZE® to develop a SC formulation of TEPEZZA (teprotumumab-trbw), indicated for the treatment of Thyroid Eye Disease, a serious, progressive and vision-threatening rare autoimmune disease,1 potentially shortening drug administration time, reducing healthcare practitioner time and offering additional flexibility and convenience for patients.
Under the terms of the agreement, Horizon will make an upfront payment of $30 million to Halozyme and is obligated to make potential future payments of up to $160 million in the aggregate, subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also be entitled to receive mid-single digit royalties on sales of commercialized medicines using the ENHANZE® technology.
"Our goal with all of our medicines is to optimize the patient experience," said Tim Walbert, chairman, president and chief executive officer, Horizon. "As we continue to explore subcutaneous administration for TEPEZZA to provide greater flexibility for patients and physicians, access to the ENHANZE® technology, which has been deployed successfully in multiple biologics, represents an important step in our development efforts."
"We are thrilled to announce our tenth collaboration and license agreement for ENHANZE® and look forward to working closely with Horizon to develop TEPEZZA with ENHANZE®," said Dr. Helen Torley, president and chief executive officer, Halozyme. "The launch of TEPEZZA has been one of the most successful and exciting launches in rare disease medicine and is making a difference in the lives of patients suffering from Thyroid Eye Disease."
Horizon represents Halozyme's tenth global collaboration and license partner for the ENHANZE® technology. These collaborations cover more than 50 therapeutic targets and include five commercialized products to date.
Big buy of DEC $44 calls going on
The jig is up. Every Derp gets his day.
Wells Fargo raises Price Target to $60 from $39
Thanks, Dew. [EOM]
Of course on the very day I observed that volume appeared to be tailing off it exploded in unheard of proportions. LOL!
21 million shares traded. That's definintely an astounding record here. I guess things are different now that HALO is on the list of 400.
Specifically: RSI up near 80, volume is starting to tail off, gap at $34, so I'd say there's going to be a pullback at some point soon and a period of consolidation below today's record intraday high.
Any new news would change that of course!
Any new 52 week high is also an all time high for HALO
The chart is looking very tired, so I'm pretty sure you'll get your chance.
Anybody worried about that gap at $34?
I think fair value is now $40 so I'm not inclined to sell calls here. By the middle of next year it will be $50, IMHO, and the buyout price will be around $100. I'm holding.
-Fritz
Wow a millions shares traded in first 20 minutes. Never saw that before.
Thanks for posting that. Really unexpected and should support the move upwards.
-Fritz
Thanks. You've pointed to Darzalex as the near term engine many times and that is exactly what has happened.
Using my valuation theory of HALO as a quasi-dividend stock, current guidance of $.80 per share makes this a $40.00 stock right now (making that a 2% return - good money these days).
We should see a significant move by weeks end, and not just in analysts' talk.
Good luck!
-Fritz
Anyone listen to the call? I haven't had time yet. Maybe tomorrow.
Raising guidance in the PR should push this into the mid-thirties eventually.
Good luck!
-Fritz
[OT] That's a fun factoid, but even more fascinating is that there exists a website called time.gov LOL!
The "We are getting hammered by competition therefore we are raising prices" strategy does not seem an effective course to me.
Good find, thanks. Always nice to see the partners moving forward.
There was a conflicting study which indicated that NSAIDS were associated with increased the rick of death, so I find this interesting but not convincing.
I have noted over the past year or two the large institutional ownership of this stock but the current levels surprise even me. Thanks for the link.
Good luck!
-Fritz
I haven't checked in here in a while. Who was locked up?
Thanks,
-Fritz
Today's move is all the more notable because it is in opposition to the down draft from the IBB and XBI. Volume continues to impress.
Yes, you called it! Impressive volume in the first 30 minutes of trading.
Looks like the next leg up has started.
Nice move back up near all time highs on pretty good volume.